Solid dispersion technologies

Advanced Drug Formulation Design to Optimize Therapeutic Outcomes

Volumn , Issue , 2007, Pages 451-492

  Miller, Dave A ^a   McGinity, James W ^a   Williams, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971329242     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (72)

1. Amidon GL, Lennernas H, Shah VP, Crison JR. Theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12(3):413–20.
2. Lipinski CA. Avoiding investment in doomed drugs, is poor solubility an industry wide problem? Curr Drug Dis 2001; 4:17–9.
3. Tabibi SE, Rhodes CT. Disperse Systems. In: Banker GS, Rhodes CT, eds. Modern Pharmaceutics, 3rd edn. New York, NY: Marcel Dekker, Inc.; 1996: 299–331.
4. Rogers TL, Hu JH, Yu ZS, Johnston KP, Williams III RO. A novel particle engineering technology: spray-freezing into liquid. Int J Pharm 2002; 242(1–2): 93–100.
5. Hu J, Johnston KP, Williams III RO. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind Pharm 2004; 30(3):233–45.
6. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharma Biopharm 2000; 50(1):47–60.
7. Reverchon E. Supercritical antisolvent precipitation of micro-and nano-particles. J Supercrit Fluids 1999; 15(1):1–21.
8. Palakodaty S, York P. Phase behavioral effects on particle formation processes using supercritical fluids. Pharm Res 1999; 16(7):976–85.
9. Matson DW, Peterson RC, Smith RD. Production of fine powders by the rapid expansion of supercritical fluid solutions. Adv Ceramics 1987; 21:109.
10. Dixon DJ, Johnston KP, Bodmeier RA. Polymeric materials formed by precipitation with a compressed fluid antisolvent. AIChE J 1993; 39:127–39.
11. Mumenthaler M, Leuenberger H. Atmospheric spray-freeze drying: a suitable alternative in freeze-drying technology. Int J Pharm 1991; 72(2):97–110.
12. Briggs AR, Maxwell TJ, inventors; Process for Preparing Powder Blends. US Patent 3,721,725. 1973.
13. Dunn DB, Masavage GJ, Sauer HA, inventors; Method of Freezing Solution Droplets and the Like Using Immiscible Refrigerants of Differing Densities. US Patent 3,653,222. 1972.
14. Hebert PF, Healy HS, inventors; Production Scale Method of Forming Microparticles. US Patent 5,922,253. 1999.
15. Evans JC, Scherzer BD, Tocco CD, et al. Preparation of nanostructured particles of poorly water soluble drugs via a novel ultra-rapid freezing technology. Poly Mater Sci Eng (2003) 2003; 89:742.
16. Law D, Wang W, Schmitt EA, Qiu Y, Krill SL, Fort JJ. Properties of rapidly dissolving eutectic mixtures of poly(-ethylene glycol) and fenofibrate: the eutectic microstructure. J Pharm Sci 2003; 92:505–15.
17. Guivarc’h P-H, Vachon MG, Fordyce D. A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions. Clin Ther 2004; 26(9):1456–69.
18. Sant VP, Smith D, Leroux J-C. Enhancement of oral bioavailability of poorly water-soluble drugs by poly(ethylene glycol)-block-poly(alkyl acrylate-co-methacrylic acid) self-assemblies. J Control Release 2005; 104 (2):289–300.
19. Sant VP, Smith D, Leroux J-C. Novel pH-sensitive supramolecular assemblies for oral delivery of poorly water soluble drugs: preparation and characterization. J Control Release 2004; 97(2):301-12.
20. Ambike AA, Mahadik KR, Paradkar A. Spray-dried amorphous solid dispersions of simvastatin, a low Tg drug: in vitro and in vivo evaluations. Pharm Res 2005; 22(6):990–8.
21. Kinoshita M, Baba K, Nagayasu A, et al. Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate. J Pharm Sci 2002; 91(2):362–70.
22. Verreck G, Vandecruys R, De Conde V, Baert L, Peeters J, Brewster ME. The use of three different solid dispersion formulations – melt extrusion, film-coated beads, and a glass thermoplastic system – to improve the bioavailability of a novel microsomal triglyceride transfer protein inhibitor. J Pharm Sci 2004; 93(5):1217–28.
23. Dannenfelser R-M, He H, Joshi Y, Bateman S, Serajuddin ATM. Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. J Pharm Sci 2004; 93(5):1165–75.
24. Levis KA, Lane ME, Corrigan OI. Effect of buffer media composition on the solubility and effective permeability coefficient of ibuprofen. Int J Pharm 2003; 6:49–59.
25. McNeil-Motrin Ò. (ibuprofen suspension, oral drops, chewable tablets, caplets) prescribing information. 56 ed. Montvale, NJ: Medical Economics Company Inc; 1994.
26. Klueglich M, Ring A, Scheuerer S, et al. Ibuprofen extrudate, a novel, rapidly dissolving ibuprofen formulation: relative bioavailability compared to ibuprofen lysinate and regular ibuprofen, and food effect on all formulations. J Clin Pharmacol 2005; 45(9):1055–61.
27. Lewis J. Solid Solutions for Insoluble Substances. Drug Delivery Report 2006; Spring/Summer:62–3.
28. Breitenbach J, Magerlein M. Melt-Extruded Molecular Dispersion. New York, NY: Marcel Dekker; 2003.
29. Geisslinger G, Dietzel K, Bezler H, Nuernberg B, Brune K. Therapeutically relevant differences in the pharmacokinetical and pharmceutical behavior of ibuprofen lysinate as compared to ibuprofen acid. Int J Clin Pharmacol Ther Toxicol 1989; 27:324–8.
30. Bell R, Black L, Harries R, et al. The discovery and characterization of selective cyclooxygenase-2 inhibitors. Inflamm Res 2000; 49:S101.
31. Chen Y, Zhang GGZ, Neilly J, Marsh K, Mawhinney D, Sanzgiri YD. Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-68. Int J Pharm 2004; 286(1–2):69–80.
32. Collett JH, Popli H. Poloxamer. Washington, DC: American Pharmaceutical Association; 2001.
33. Shin SC, Cho CW. Physicochemical characterizations of piroxicam-poloxamer solid dispersion. Pharm Dev Tech 1997; 2:403–7.
34. Passerini N, Albertini B, Gonzoalez-Rodro guez ML, Cavallari C, Rodriguez L. Preparation and characterization of ibuprofen-poloxamer 188 granules obtained by melt granulation. Eur J Pharm Sci; 2002:71–8.
35. Chowdary KPR, Babu KVVS. Dissolution, bioavailability and ulcerogenic studies on solid dispersions of indomethacin in water-soluble cellulose polymers. Drug Dev Ind Pharm 1994; 20(5):799–813.
36. Tagliati CA, Kimura E, Nothenberg MS, Santos SRJC, Oga S. Pharmacokinetic profile and adverse gastric effect of zinc-piroxicam in rats. Gen Pharmacol 1999; 13:67–71.
37. Yuksel N, Karatas A, Ozkan Y, Savaser A, Ozkan SA, Baykara T. Enhanced bioavailability of piroxicam using Gelucire 44/14 and Labrasol: in vitro and in vivo evaluation. Eur J Pharma Biopharm 2003; 56(3):453–9.
38. Etienne MC, Milano G, Rene N, et al. Improved bioavailability of a new oral preparation of medroxyprogesterone acetate. J Pharm Sci 1991; 80(12):1130–2.
39. Pannuti F, Martoni A, Di Marco AR, Piana E. Eur J Cancer 1979; 15:593–601.
40. Carli F, inventor Farmitalia Carlo Erba S.p.A. Pat. # 4,632,828, assignee. Pharmaceutical composition US. 1986.
41. Johnson JR, Priestman IJ, Fotherby K, Kelly KA, Priestman SG. An evaluation of high-close medroxyprogesterone acetate therapy in women with advanced breast cancer. Br J Cancer 1984; 1984(50):363–6.
42. Kondo N, Iwao T, Hirai K, et al. Improved oral absorption of enteric coprecipitates of a poorly soluble drug. J Pharm Sci 1994; 83(4):566–70.
43. Kondo N, Iwao T, Kikuchi M, et al. Pharmacokinetics of a micronized, poorly water-soluble drug, HO-221, in experimental animals. Biol Pharm Bull 1993; 16 (8):796–800.
44. Palmieri GF, Cantalamessa F, Di Martino P, Nasuti C, Martelli S. Lonidamine Solid dispersions: in vitro and in vivo evaluation. Drug Dev Ind Pharm 2002; 28 (10):1241–50.
45. Breitenbach J. Melt extrusion can bring new benefits to HIV therapy: the example of Kaletra tablets. Am J Drug Deliv 2006; 4(2):61–4.
46. Abbott_Laboratories. KALETRAÒ (lopinavir/ritonavir) tablets (lopinavir/ritonavir) oral solution [prescring information; online]. Available from URL: http://wwwrxabbottcom/pdf/kaletratabpipdf2005;[Accessed December 14, 2006].
47. Law D, Schmitt EA, Marsh KC, et al. Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations. J Pharm Sci 2004; 93(3):563–70.
48. Law D, Krill SL, Schmitt EA, et al. Physicochemical considerations in the preparation of amorphous ritonavir/PEG 8000 solid dispersions. J Pharm Sci 2001; 90(8):1015–25.
49. Aungst BJ, Nguyen NH, Bulgarelli JP, Oates-Lenz K. The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds. Pharm Res 2000; 17: 1175–80.
50. De Jaeghere F, Allemann E, Kubel F, et al. Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state. J Control Release 2000; 68(2):291–8.
51. Janssen LP. Sporanox (Itraconazole Capsules) Prescribing Information. Available from URL: http://wwwsporanoxcom2006; Janssen Pharmaceutica N.V.(Beerse, Belgium).
52. Six K, Daems T, de Hoon J, et al. Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. Eur J Pharm Sci 2005; 24(2-3): 179–86.
53. Peeters J, Neeskens P, Tollenaere JP, Van Remoortere P, Brewster M. Characterization of the interaction of 2-hydroxypropyl-B-cyclodextrin with itraconazole at pH 2, 4 and 7. J Pharm Sci 2002; 91:1414–22.
54. Marriner SE, Morris DL, Dickson B, Bogan JA. Pharmacokinetics of albendazole in man. Eur J Clin Pharmacol 1986; 30:705–8.
55. Jung H, Hurtado M, Sanchez M, Medina MY, Sotelo J. Clinical pharmacokinetics of albendazole in patients with brain cysticercosis. J Clin Pharmacol 1992; 32:28–31.
56. Kohri N, Yamayoshi Y, Iseki K, Sato N, Todo S, Miyazaki K. Effect of gastric pH on the bioavailability of albendazole. Pharm Pharmacol Commun 1998; 4: 267–70.
57. Kohri N, Yamayoshi Y, Xin H, et al. Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique. J Pharm Pharmacol 1999; 51(2):159–64.
58. Maheswaran AM, ed. Mosby’s Drug Consult. 16 edn. St. Louis, Missouri: Mosby, Inc.; 2006.
59. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharma Biopharm 2004; 58(2):265–78.
60. Wong SM, Kellaway IW, Murdan S. Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. Int J Pharm 2006; 317(1):61–8.
61. Hane K, Fujioka M, Namiki Y, et al. Physico-chemical properties of (–)-1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R-17-allyl-1,14-dihy-droxy-12-[(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetrametyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9] octacos-18-ene-2,3,10,16-tetrone hydrate (FK-506). Iyakuhin Kenkyu 1992; 23: 33–43.
62. Honbo T, Kobayashi M, Hane K, Hata T, Ueda Y. The oral dosage form of FK-506. Transpl Proc 1987; 19:17–22.
63. Yamashita K, Nakate T, Okimoto K, et al. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm 2003; 267 (1–2):79–91.
64. Ismailos G, Reppas C, Dressman JB, Macheras P. Unusual solubility behaviour of cyclosporin A in aqueous media. J Pharm Pharmacol 1991; 43: 287–9.
65. Gibson M. Product Optimisation. In: Gibson M, ed. Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form. Boca Raton, FL: CRC Press; 2001.
66. Liu C, Wu J, Shi B, Zhang Y, Gao T, Pei Y. Enhancing the Bioavailability of Cyclosporine A Using Solid Dispersion Containing Polyoxyethylene (40) Stearate. Drug Dev Ind Pharm 2006; 32(1):115–23.
67. Vaughn JM, T. MJ, Crisp MT, Johnston KP, Williams RO, III. Supersaturation produces high bioavailability of amorphous danazol particles formed by evaporative precipitation into aqueous solution and spray freezing into liquid technologies. Drug Dev Ind Pharm 2006; 32(5):559–67.
68. Sarkari M, Brown J, Chen XX, Swinnea S, Williams RO, Johnston KP. Enhanced drug dissolution using evaporative precipitation into aqueous solution. Int J Pharm 2002; 243(1–2):17–31.
69. Yakou S, Umehara K, Sonobe T, Nagai T, Sugihara M, Fukuyama Y. Particle size dependency of dissolution rate and human bioavailability of phenytoin in powders and phenytoin-polyethylene glycol solid dispersions. Chem Pharm Bull 1984; 32(10):4130–6.
70. Doherty C, York P. The in-vitro pH-dissolution dependence and in-vivo bioavailability of frusemide-PVP solid dispersions. J Pharm Pharmacol 1989; 41(2):73–8.
71. Tashtoush BM, Al-Qashi ZS, Najib NM. In vitro and in vivo evaluation of glibenclamide in solid dispersion systems. Drug Dev Ind Pharm 2004; 30(6): 601–7.
72. Serajuddin ATM. Solid disperison of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 1999; 88(10):1058–66.